Invacare Corporation (IVC)
(Delayed Data from NYSE)
$7.57 USD
+0.33 (4.56%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.57 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.57 USD
+0.33 (4.56%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.57 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Thermo Fisher (TMO) Rides on Pharma & Biotech Amid Pandemic
by Zacks Equity Research
Customers in Thermo Fisher's (TMO) industrial and applied end markets get affected by business disruptions due to the pandemic.
Integra (IART) Arms Grow Sequentially Despite Supply Issues
by Zacks Equity Research
Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically.
Bruker (BRKR) Rides on Product Launches Amid COVID-19 Woes
by Zacks Equity Research
Within Bruker's (BRKR) Nano Group Semiconductor metrology revenues have been steady with order rates improving as semi metrology equipment markets are witnessing a rebound.
LabCorp's (LH) New Antigen Test to Spot Active COVID-19 Virus
by Zacks Equity Research
LabCorp's (LH) new antigen test is the newest development to detect COVID-19 infection at every single stage, from diagnostic testing to vaccination trails.
The Zacks Analyst Blog Highlights: ResMed, Invacare, Fresenius, Henry Schein and Quest Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ResMed, Invacare, Fresenius, Henry Schein and Quest Diagnostics
4 MedTech Underperformers Poised for a Turnaround in 2021
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks which are expected to provide long-term gains in 2021.
AmerisourceBergen (ABC), WBA Ink Deal to Focus on Core Arms
by Zacks Equity Research
AmerisourceBergen (ABC) and Walgreens (WBA) enter into a key strategic deal to boost focus on core businesses, while extending their partnership.
Invacare (IVC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invacare (IVC) delivered earnings and revenue surprises of 47.37% and 3.72%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Invacare (IVC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Invacare (IVC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Invacare (IVC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Invacare (IVC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Invacare (IVC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invacare (IVC) delivered earnings and revenue surprises of 30.00% and 0.20%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Invacare (IVC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Invacare (IVC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Vapotherm, Inogen and Invacare
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vapotherm, Inogen and Invacare
3 Stocks in Focus as Coronavirus Boosts Medical Oxygen Demand
by Manaswita Ghosh Dutta
Oxygen therapy has emerged as a necessity for COVID-19 patients.
Invacare (IVC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Invacare (IVC) delivered earnings and revenue surprises of 28.57% and -2.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Invacare (IVC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Invacare (IVC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Invacare (IVC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invacare (IVC) delivered earnings and revenue surprises of -10.71% and 0.67%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Invacare (IVC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Invacare (IVC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Invacare (IVC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invacare (IVC) delivered earnings and revenue surprises of 0.00% and -0.79%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Invacare (IVC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Invacare (IVC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerner and naviHealth Extend Partnership, Boost EHR Service
by Zacks Equity Research
Cerner (CERN) and naviHealth coordinate to provide EHR offering that is expected to benefit health care providers in the form of affordable and accessible health care centered on the patient.
Here's Why You Should Bet on Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across its segments and prudent acquisitions.
BD Introduces New Product to Reduce the Risk of Sepsis
by Zacks Equity Research
BD introduces new FDA cleared product to lower the risk of sepsis and combat platelet contamination.
Will Invacare Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Invacare.
New Strong Buy Stocks for March 11th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday